Jump to ContentJump to Main Navigation
Show Summary Details

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter / Tate, Jillian R.


IMPACT FACTOR increased in 2015: 3.017
Rank 5 out of 30 in category Medical Laboratory Technology in the 2014 Thomson Reuters Journal Citation Report/Science Edition

SCImago Journal Rank (SJR) 2015: 0.873
Source Normalized Impact per Paper (SNIP) 2015: 0.982
Impact per Publication (IPP) 2015: 2.238

249,00 € / $374.00 / £187.00*

Online
ISSN
1437-4331
See all formats and pricing

 


Select Volume and Issue
Loading journal volume and issue information...

30,00 € / $42.00 / £23.00

Get Access to Full Text

Evaluation of ovarian cancer biomarkers in subjects with benign asbestos-related pleural diseases

Eun-Kee Park1, 2 / Anthony R. Johnson3 / Deborah H. Yates1 / 2

1Department of Thoracic Medicine, St. Vincent's Hospital, Darlinghurst, Sydney, NSW 2010, Australia

2Faculty of Medicine, School of Medical Sciences, University of New South Wales, Sydney, NSW 2031, Australia

3Department of Respiratory Medicine, Liverpool Hospital, Sydney, NSW 2170, Australia

Corresponding author: Paul S. Thomas, MD, Department of Respiratory Medicine, Prince of Wales Hospital, Randwick, NSW 2031, Australia Phone: +61-2-9382-4620, Fax: +61-2-9382-4627

Citation Information: Clinical Chemistry and Laboratory Medicine. Volume 49, Issue 1, Pages 147–150, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: 10.1515/CCLM.2011.015, October 2010

Publication History

Received:
2010-05-04
Accepted:
2010-07-22
Published Online:
2010-10-20

Abstract

Background: Mesothelioma and ovarian cancer have been reported to have a similar pathogenesis, and for this reason it was hypothesized that there may be biomarkers in common and possibly associated with benign pleural diseases caused by asbestos exposure.

Methods: Serum biomarkers including insulin-like growth factor-II (IGF-II), leptin, prolactin and vascular endothelial growth factor (VEGF) were measured in an observational study of subjects with benign asbestos-related pleural diseases (BARPD) (n=24) and healthy subjects with an asbestos exposure history (n=12).

Results: Mean serum IGF-II and VEGF concentration in healthy subjects with a history of asbestos exposure were higher than those with BARPD. Mean serum concentrations of leptin and prolactin showed opposite trends when compared to IGF-II and VEGF concentrations among these groups.

Conclusions: The results suggest that IGF-II and VEGF concentrations are lower in BARPD, similar to studies of ovarian cancer. This finding warrants further investigation with malignant asbestos-related diseases.

Keywords: asbestos; benign asbestos-related diseases; biomarker; ovarian cancer

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Alfonso Cristaudo, Alessandra Bonotti, Silvia Simonini, Rossella Bruno, and Rudy Foddis
Biomarkers in Medicine, 2011, Volume 5, Number 2, Page 261

Comments (0)

Please log in or register to comment.